Select Publications

Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39. PMID: 35820547.

Simpson EL, Gooderham M, Wollenberg A, Armstrong AW, et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023; DOI:10.1001/jamadermatol.2022.5534.

Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021;157(8):940-946.

Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;85(3):572-581. doi:10.1016/j.jaad.2021.02.057. PMID: 33631216.

Armstrong AW, Amato D, Huster W, Ojeh C, Van Voorhees AS. Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies. J Am Acad Dermatol. 2021;85(2):330-336. PMID: 31562945.

Merola JF, Tian H, Patil D, Richardson C, Scott A, Chen YH, Kim N, Hur P, Armstrong AW. Incidence and Prevalence of Psoriatic Arthritis in Patients With Psoriasis Stratified by Psoriasis Disease Severity: Retrospective Analysis of a US Electronic Health Records Database. J Am Acad Dermatol. 2021; doi:10.1016/j.jaad.2021.09.019. PMID: 34547358.

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;398(10385):1680-1699. PMID: 33812489.

Armstrong AW, Puig L, Joshi A, et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-Analysis. JAMA Dermatol. 2020;156(3):258-269. PMID: 32022825.

Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960. DOI:10.1001/jama.2020.4006.

Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Menter A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. PMID: 30772098.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113.

Reich K, Armstrong AW, Langley RG, et al. Guselkumab Versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results From a Phase 3, Randomised Controlled Trial. Lancet. 2019;394(10201):831-839. PMID: 31402114.

Armstrong AW, Chambers CJ, Maverakis E, et al. Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. JAMA Netw Open. 2018;1(6):e183062. PMID: 30646223; PMCID: PMC6324453.

Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb A, Armstrong AW. Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. JAMA Dermatol. 2018;154(10):1137-1144.

Adler BL, Kornmehl H, Armstrong AW. Antibiotic Resistance in Acne Treatment. JAMA Dermatol. 2017; DOI:10.1001/jamadermatol.2017.1297.

Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290-298.

Armstrong AW. Psoriasis. JAMA Dermatol. 2017;153(9):956.

Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Under-treatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol. 2017;149(10):1180-1185.

Kimball AB, Okun MM, Williams DA, Armstrong AW, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016; DOI:10.1056/NEJMoa1504370.

Armstrong AW, Guérin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015;72(6):968-977.

Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol. 2013;149(6):717-721. doi:10.1001/jamadermatol.2013.133. PMID: 23783152.

Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654-662. PMID: 23360868.

Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84-91. PMID: 23407990.

Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; DOI:10.1001/jama.2020.4006.